Recursion leadership change sees Najat Khan taking over as CEO, focusing on AI-driven drug development results.
Author: PharmaSignal News Desk
FDA voucher program raises ethical concerns as experts warn of procedural risks and market impacts.
South Africa compulsory license urged for HIV drug to enhance access and support WHO goals.
Pfizer mRNA flu shot demonstrated better protection than standard vaccines, impacting millions.
Eli Lilly $1 Trillion market value milestone achieved through obesity drug success, surpassing peers.
Pfizer settlement Texas involves $41.5 million payment over ADHD drug manufacturing flaws.
FDA quick clarifications allow biotechs to email agency staff, enhancing communication and expediting drug development processes.
Pfizer settlement Texas involves $41.5 million over allegations of altered testing methods for an ADHD drug.
Contineum MS trial failure leads to a significant share drop, affecting Johnson & Johnson’s interest.
Novo Nordisk is set to release pivotal Phase 3 data on semaglutide’s impact on Alzheimer’s, potentially reshaping treatment.